Neoadjuvant treatment for rectal cancer-A value-based proposition.

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Neoadjuvant chemoradiation followed by resection and adjuvant chemotherapy is the current standard for locally advanced rectal cancer.
• This established treatment paradigm is increasingly being re-evaluated based on emerging clinical data.

Purpose of the Study:

• To discuss the evolving role of neoadjuvant chemoradiation in rectal cancer treatment.
• To identify patient subgroups who may not require radiation therapy.
• To explore potential benefits of radiation for specific patient populations.

Main Methods:

• Review of current literature and emerging data on neoadjuvant chemoradiation for rectal cancer.
• Discussion of treatment de-escalation and escalation strategies.
• Analysis of factors influencing treatment decisions.

Main Results:

• The established neoadjuvant chemoradiation approach is being challenged by new evidence.
• There is a need to personalize treatment based on individual patient characteristics and tumor biology.
• Identifying patients for whom radiation can be omitted or is beneficial is a key future challenge.

Conclusions:

• The standard treatment for locally advanced rectal cancer may require modification.
• Future research should focus on tailoring neoadjuvant therapy to optimize oncologic outcomes.
• Personalized treatment strategies are essential for improving rectal cancer care.